Viewing Study NCT01739634


Ignite Creation Date: 2025-12-25 @ 2:37 AM
Ignite Modification Date: 2025-12-30 @ 4:16 AM
Study NCT ID: NCT01739634
Status: UNKNOWN
Last Update Posted: 2012-12-03
First Post: 2012-11-29
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
Sponsor: Salient Pharmaceuticals Incorporated
Organization:

Study Overview

Official Title: The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
Status: UNKNOWN
Status Verified Date: 2012-11
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Diarrhea in patients with MTC (Medullary Thyroid Cancer) can be debilitating and, in some cases life threatening. Findings in such patients include volume depletion, renal insufficiency, and electrolyte disorders. Diarrhea can also lead to increased cost of care, reduced quality of life, and treatment delays. Not all patients benefit from conventional anti-diarrheal therapy. CASAD is proven to reduce diarrhea in humans and animals. Clays have water-binding effects, increase the absorptive capacity of the intestinal mucosa, and absorb the excess cytokines which are possible mechanisms of diarrhea in MTC. In this study, we will investigate if starting 1 g CASAD three times a day will ameliorate the severity of diarrhea in patients with MTC. Diarrhea in patients with MTC can be debilitating and, in some cases life threatening. Findings in such patients include volume depletion, renal insufficiency, and electrolyte disorders. We hypothesize that adding CASAD 3 grams/day will reduce the incidence and ameliorate the severity of diarrhea in patients with MTC.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: